

Fever under 5 Committee meeting

Date: 21/06/2019

Location: NICE Manchester

Minutes: Final

Committee members present:	
Pramod Mainie (Chair)	present for notes 1- 7
Srinivas Bandi (SB)	present for notes 1- 5
Sarah Beswick (SBE)	present for notes 1- 7
Nathan Griffiths (NG)	present for notes 1- 6
Nazia Hussain (NH)	present for notes 1- 7
Rachael McCormack (RM)	present for notes 2- 7
Zdenka Reinhardt (ZR)	present for notes 2- 7
Andrew Riordan (AR)	present for notes 1- 7

In attendance:		
Rupert Franklin	Senior Commissioning Manager	present for notes 1- 7
James Hall (JH)	Medical Editor	present for notes 1- 7
Kathryn Hopkins (KH)	Technical Adviser	present for notes 1- 7
Vonda Murray (VM)	Project Manager	present for notes 1- 7
Bernadette Li	Technical Adviser - Health Economics	present for notes 1- 7

Observers:	
Emma Chambers	Public Involvement Adviser
Isabella Henry	Finance Apprentice
Jenny Walsh	Accounts Assistant

Apologies:	
Sarah Catchpole	NICE – Medical Editor
Gabriel Rogers	NICE – Technical Adviser - Health Economics
Edgar Masanga	NICE – Technical Adviser -
Toby Mercer	NICE – Technical Analyst
Martin Richardson	Committee member

1. Welcome, apologies, objectives, declaration of interest

The Chair welcomed the Committee members and attendees to the 1st meeting on Fever under 5.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included:

- Review of the evidence, and draft recommendations for children with fever, what signs/symptoms are predictive of Kawasaki disease

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Kawasaki disease.

The following declarations of interest were made;

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Srinivas Bandi	Consultant Paediatrician, Leicester Royal Infirmary, Leicester	Feb 2019 Co-principal investigator for the CAP-IT trail. The study is to look, if lower doses and shorter children, is just as effective as higher doses and longer duration of treatmentduration of antibiotic treatment for pneumonia in	Direct non-financial personal and professional	Declare and participate Not specific to any topic covered in the scope of the guideline.
Srinivas Bandi	Consultant Paediatrician, Leicester Royal Infirmary, Leicester	Feb 2019 Executive committee member – Children’s HIV Association (CHIVA)	Direct non-financial personal and professional	Declare and participate Not specific to any topic covered in the scope of the guideline.
Sarah Beswick	Lay member	Feb 2019 Member of the NICE multiple obstetric guidelines (Update)	Direct financial	Declare and participate Not specific to any topic covered in the scope of the

		committee, published March 2019		guideline.
Nathan Griffiths	Clinical Lead for Paediatric Unscheduled Care, Salford Royal, Salford	Feb 2019 Provide clinical training/education on paediatric topics to healthcare staff for a private training company on a freelance/ad- hoc basis. Does include education of the assessment of the child with fever	Direct financial	Declare and participate, not specific to Kawasaki disease
Rachael McCormack	Lay member	Feb 2019 Societi Foundation Founder (Chair)	Direct non- financial personal and professional	Declare and participate
Rachael McCormack	Lay member	Feb 2019 Chair the UK Kawasaki Disease Steering Group	Direct non- financial personal and professional	Declare and participate
Rachael McCormack	Lay member	Feb 2019 Societi Foundation donation (£10,000) to develop an e- learning module – SOBI	In-direct financial	Declare and participate
Rachael McCormack	Lay member	Feb 2019 Societi Foundation donation (£1,500) - from Roche Diagnostics - for supporting parliamentary engagement work	In-direct financial	Declare and participate
Rachael McCormack	Lay member	Feb 2019 Trail co- investigator - c4c (conect4children), European trail on efficacy of steroids in acute Kawasaki Disease therapy – for the reduction of coronary artery	Direct non- financial personal and professional	Declare and participate

		aneurysms		
Andrew Riordan	Consultant in Paediatric Infectious Diseases and Immunology, Alder Hey Children's NHS Foundation, Liverpool	June 2019 Medical advisor, Meningitis Research Foundation	Direct financial (expenses only)	Declare and participate Not specific to any topic covered in the scope of the guideline.
Andrew Riordan	Consultant in Paediatric Infectious Diseases and Immunology, Alder Hey Children's NHS Foundation, Liverpool	Associate Editor, Archives of Disease in Childhood (a BMJ/ RCPCH journal) Reviews papers, process the editorial committee's recommendations (to accept or reject). Participates in "Auctions" where a number of Editors discuss which papers could be published. Suggests which papers should be accepted, but the "Auction" or the Editor in Chief decides.	Direct financial	Declare and participate Not involved in making the decision if an article is to be published
Damian Roland	Consultant in Paediatric Emergency Medicine, University Hospitals of Leicester NHS Trust, Leicester	February 2019 Programme board member for the NHS England/Royal College of Physicians Ireland - National Paediatric Early Warning System implementation programme	Direct non-financial personal and professional	Declare and participate Not specific to any topic covered in the scope of the guideline.
Damian Roland	Consultant in Paediatric Emergency Medicine,	Clinical advisor to Societi – a charity which aims to raise awareness of		Declare and participate, provides general clinical advice to

	University Hospitals of Leicester NHS Trust, Leicester	Kawasakis Disease.	the charity, which aims to raise awareness of the disease.
<p>The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.</p>			
<p>2. Technical training</p>			
<p>The Chair introduced KH, Technical Adviser, who provided an overview of the evidence review process, types of studies and how studies are assessed. The Chair thanked KH for their presentation.</p>			
<p>3. RQ1 - In children with fever, what symptoms and signs or combinations of symptoms and signs are predictive of Kawasaki disease?</p> <ul style="list-style-type: none"> • Presentation of clinical evidence 			
<p>KH presented the clinical evidence what symptoms and signs or combinations of symptoms and signs are predictive of Kawasaki disease. The Committee then discussed the issues presented in relation to this guideline. The Chair thanked KH for their presentation.</p>			
<p>4. RQ1 - In children with fever, what symptoms and signs or combinations of symptoms and signs are predictive of Kawasaki disease?</p> <ul style="list-style-type: none"> • Health economics 			
<p>BL presented on the topic of health economics. The Chair thanked BL for their presentation.</p>			
<p>5. RQ1 - In children with fever, what symptoms and signs or combinations of symptoms and signs are predictive of Kawasaki disease?</p> <ul style="list-style-type: none"> • Draft recommendation 			
<p>The Committee discussed symptoms and signs of Kawasaki disease</p>			
<p>6. RQ1 - In children with fever, what symptoms and signs or combinations of symptoms and signs are predictive of Kawasaki disease?</p> <ul style="list-style-type: none"> • Draft recommendation continued 			
<p>The Committee continued the discussion on symptoms and signs of Kawasaki</p>			

disease
7. Next steps, AOB
No other business. The Chair thanked the committee for their time and contribution to the meeting.

Date of next meeting: 01/10/2019

Location of next meeting: London